Gsk (GSK) Net Cash Flow (2009 - 2026)

Gsk (GSK) has 18 years of Net Cash Flow data on file, last reported at -$404.1 million in Q3 2026.

• For the quarter ending Q3 2026, Net Cash Flow changed N/A year-over-year to -$404.1 million; the trailing twelve-month figure through Sep 2026 stood at $13.5 billion (changed N/A YoY), and the FY2025 full-year result was -$235.4 million, down 130.75% from the prior year.
• Net Cash Flow was -$404.1 million for Q3 2026 at Gsk, down from $6.3 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $7.7 billion in Q4 2025 to a low of -$7.4 billion in Q4 2022.
• A 5-year average of $1.9 billion and a median of $1.8 billion in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 1523.89% in 2022 and soared 439.8% in 2025, its largest moves.
• Gsk's Net Cash Flow stood at -$7.4 billion in 2022, then jumped by 174.89% to $5.6 billion in 2023, then sank by 41.21% to $3.3 billion in 2024, then jumped by 134.12% to $7.7 billion in 2025, then sank by 105.28% to -$404.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$404.1 million in Q3 2026, $6.3 billion in Q2 2026, and -$71.5 million in Q1 2026.